No Result
View All Result
SUBMIT YOUR ARTICLES
  • Login
Thursday, October 2, 2025
TheAdviserMagazine.com
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
No Result
View All Result
TheAdviserMagazine.com
No Result
View All Result
Home Medicare

Breaking Down Why Medicare Part D Premiums Are Likely To Go Up

by TheAdviserMagazine
2 months ago
in Medicare
Reading Time: 6 mins read
A A
Breaking Down Why Medicare Part D Premiums Are Likely To Go Up
Share on FacebookShare on TwitterShare on LInkedIn


Medicare enrollees who buy the optional Part D drug benefit may see substantial premium price hikes — potentially up to $50 a month — when they shop for next year’s coverage.

Such drug plans are used by millions of people who enroll in what is called original Medicare, the classic federal government program that began in 1965 and added a drug benefit only in 2006. The drug plans are offered through private insurers, and enrollees must pay monthly premiums.

It’s not known whether insurers will pursue the maximum increase allowed, as premium prices for next year won’t be revealed until closer to open enrollment, which starts Oct. 15.

Increases are expected to mainly affect stand-alone Part D plans, not the drug coverage offered as part of Medicare Advantage, the private sector alternative to original Medicare. More on that later.

Policy experts say premiums are likely to go up for several reasons, including increased use of some higher-cost prescription drugs; a law that capped out-of-pocket spending for enrollees; and changes in a program aimed at stabilizing price increases that the Trump administration has continued but made less generous.

One thing is surer than ever, say many policy experts: Beneficiaries should not simply roll over their existing stand-alone Medicare drug plans.

“Everyone should shop plans in open enrollment,” said Stacie Dusetzina, a professor of health policy at Vanderbilt University Medical Center.

Here are three reasons prices would rise.

Email Sign-Up

Subscribe to KFF Health News’ free Morning Briefing.

1. It’s the Spending!

Every year, insurers keep an eye on what they’re spending on drugs so they can build that into their premium estimates. Spending covers both the prices charged by drugmakers and volume, meaning how many people take the medications and how often.

And it’s up. Spending by insurers and government programs for prescription drugs in 2024 across the market grew more than 10%, which is slightly greater than in recent years, according to a research report published in last month’s issue of the American Journal of Health-System Pharmacy. Estimates are not yet available for this year’s trends.

Still, in 2024, researchers found that drug prices overall decreased slightly. Spending rose because of drugs coming on the market and increased utilization, especially for pricey weight loss drugs and another category of medications that treat various autoimmune conditions, such as rheumatoid arthritis.

Such increased use is evident in Medicare. Many beneficiaries, for example, are treated for autoimmune conditions. And even though Medicare doesn’t cover treatment for weight loss, many members have diabetes or other conditions that a new type of weight loss drugs can treat.

The Trump administration, according to The Washington Post, is considering a five-year pilot program in which Medicare Part D plans could voluntarily expand access to the drugs, which can cost more than $1,000 a month without insurance. Details have not yet been provided, but the pilot program would not begin in Medicare until 2027.

Another wild card for insurers is the Trump administration’s tariffs on businesses that purchase products made overseas, which could boost drug prices because the U.S. imports a lot of its pharmaceuticals. Much, however, remains unknown about whether drugmakers will pass along any additional tariff costs to consumers.

So, while rising spending is one factor, it isn’t the only reason next year’s premium prices are expected to go up.

2. New Out-of-Pocket Caps for Consumers

Changes made to Medicare aimed at helping people with high out-of-pocket costs for expensive medications may be a bigger factor.

Here’s why: Starting this year, Medicare enrollees have a limit on how much they must pay out-of-pocket for prescription drugs. It’s capped at $2,000, a threshold that will rise each year to cover inflation.

Lawmakers in Congress set those changes in the Inflation Reduction Act under President Joe Biden. The law also shifted a larger share of the cost of drugs used by Medicare beneficiaries from the federal program to insurers.

That $2,000 cap is a big change from previous years, when people taking expensive drugs had a higher threshold to meet annually and were on the hook to pay 5% of the drug’s cost even after meeting that amount. Those additional 5% payments ended last year under the provisions of the IRA.

Before that law passed, “people would spend $10,000 or $15,000 out-of-pocket each year just for a single drug,” Dusetzina said. “The Inflation Reduction Act was necessary to make Part D proper health insurance, but there’s a cost to do so.”

While the cap is a big help for affected consumers, the reduced amounts paid by some beneficiaries — coupled with the cost shift to insurers — could lead plans to spread their increased expenses across all policyholders through higher premiums. A growing number of health plans have also begun to require enrollees to pay a percentage of a drug’s cost, rather than a flat-dollar copay, which can lead to larger-than-expected costs at the pharmacy counter, Dusetzina said.

While consumers not currently taking high-cost specialty drugs may not see a benefit in the $2,000 cap initially, they might one day, say policy experts, who note that drugmaker prices continue to rise and that enrollees could fall ill with a condition like cancer or multiple sclerosis for which they need a very high-priced drug.

“It’s important to think not just in context of those groups who hit the cap every year, but also people are paying more in premiums to protect their future selves as well,” said Casey Schwarz, the senior counsel for education and federal policy at the Medicare Rights Center, an advocacy group.

The new prescription drug cap and other changes apply to both the stand-alone Part D drug plans and Medicare Advantage plans. But those Medicare Advantage plans are not expected to increase the drug portion of their premiums, partly because the private sector plans are paid more per member than what it costs taxpayers for the traditional program.

That means Advantage plans have far more money to add benefits, such as vision and dental coverage, which traditional Medicare does not include, or to use them to cushion the impact of rising spending on drug costs, thus limiting premium increases.

Those additional benefits are advertised to attract customers to Medicare Advantage, which also sometimes offers plans with minimal or no monthly premium costs. There are other differences between traditional Medicare and private sector plans. For example, Advantage members must stick to doctors and hospitals in the plan’s networks, and they may face more prior authorization or other hurdles than in the traditional program.

The growing difference between premiums — fueled by the extra rebates flowing to the private sector plans — “is increasingly tilting coverage toward Medicare Advantage and making traditional Medicare plus a stand-alone PDP [prescription drug plan] unaffordable for many enrollees,” said Juliette Cubanski, deputy director of the program on Medicare policy at KFF, a health information nonprofit that includes KFF Health News.

3. Trump Administration Reduced Funding Meant To Slow Premium Growth

The final factor in the premium increase equation is a program set up to slow the rise of premiums in stand-alone Part D plans.

It began under the Biden administration to offset premium increases tied to changes in the Inflation Reduction Act by temporarily injecting additional federal dollars to help insurers adjust to the new rules.

That plan sent just over $6 billion this year to Part D insurers.

And it had an effect.

The average monthly premium for a stand-alone Part D drug plan dropped 9%, from $43 last year to $39 this year, according to KFF, even when factoring in that some plans raised prices by up to $35 a month, the maximum increase allowed under the stabilization plan for this year.

In a memo released in late July, the Trump administration said it would continue the program for next year, while shaving about 40% of the funding. A government official told The Wall Street Journal that the administration felt that keeping the full funding would have mainly benefited the insurers and cost taxpayers an “enormous, excess amount.”

The stabilization effort next year will send $10 a month per enrollee to Part D insurers to help keep premiums in check, down from $15 this year. Among other changes, it allows insurers to raise premiums by as much as $50 a month, up from the $35 allowed this year.

That would be a substantial increase, Cubanski noted, although it is not clear just how many insurers would pursue the full amount.

“We did see some plans this year were taking premium increases of that $35 amount in 2025, and I fully expect we will see some plans with increases up to $50 a month” next year, she said.

Another reason to take a close look at all the options once open enrollment begins.

Julie Appleby:
[email protected],
@Julie_appleby

Related Topics

Contact Us

Submit a Story Tip



Source link

Tags: BREAKINGMedicarepartPremiums
ShareTweetShare
Previous Post

Israeli institutional investors buy Gett for $188m

Next Post

Why Big Tech Economic Impact Studies Fall Short

Related Posts

edit post
The Struggle To Afford Insurance in 2026 Hits Home

The Struggle To Afford Insurance in 2026 Hits Home

by TheAdviserMagazine
October 1, 2025
0

Dan Weissmann “An Arm and a Leg” senior producer Emily Pisacreta recently lost a job that provided her with health...

edit post
Health insurance for the unemployed

Health insurance for the unemployed

by TheAdviserMagazine
September 28, 2025
0

In the United States, nearly half of the people under the age of 65 get their health insurance from an...

edit post
Journalists Recap Coverage on Organ Harvesting, Obamacare, and Medicaid Cuts

Journalists Recap Coverage on Organ Harvesting, Obamacare, and Medicaid Cuts

by TheAdviserMagazine
September 27, 2025
0

KFF Health News Midwest correspondent Cara Anthony discussed problems with the organ transplantation industry on Apple News’ “Apple News Today”...

edit post
Listen: Young Adults Turning 26 Face Health Insurance Cliff

Listen: Young Adults Turning 26 Face Health Insurance Cliff

by TheAdviserMagazine
September 26, 2025
0

Thank you for your interest in supporting KFF Health News, the nation’s leading nonprofit newsroom focused on health and health...

edit post
Federal Funding Deadline Looms – Medicare Rights Center

Federal Funding Deadline Looms – Medicare Rights Center

by TheAdviserMagazine
September 25, 2025
0

Legislation funding the federal government expires September 30. Congress must pass another spending bill by then to avoid a shutdown,...

edit post
Final Rule and New Special Enrollment Period Will Aid Those Misled by Provider Directories

Final Rule and New Special Enrollment Period Will Aid Those Misled by Provider Directories

by TheAdviserMagazine
September 25, 2025
0

Earlier this month, we flagged important changes coming to Medicare Plan Finder (MPF) for the upcoming Fall Open Enrollment period,...

Next Post
edit post
Why Big Tech Economic Impact Studies Fall Short

Why Big Tech Economic Impact Studies Fall Short

edit post
10 Tips to Live Frugally After Retirement

10 Tips to Live Frugally After Retirement

  • Trending
  • Comments
  • Latest
edit post
What Happens If a Spouse Dies Without a Will in North Carolina?

What Happens If a Spouse Dies Without a Will in North Carolina?

September 14, 2025
edit post
California May Reimplement Mask Mandates

California May Reimplement Mask Mandates

September 5, 2025
edit post
Does a Will Need to Be Notarized in North Carolina?

Does a Will Need to Be Notarized in North Carolina?

September 8, 2025
edit post
Who Needs a Trust Instead of a Will in North Carolina?

Who Needs a Trust Instead of a Will in North Carolina?

September 1, 2025
edit post
DACA recipients no longer eligible for Marketplace health insurance and subsidies

DACA recipients no longer eligible for Marketplace health insurance and subsidies

September 11, 2025
edit post
‘Quiet luxury’ is coming for the housing market, The Corcoran Group CEO says. It’s not just the Hamptons, Aspen, and Miami anymore

‘Quiet luxury’ is coming for the housing market, The Corcoran Group CEO says. It’s not just the Hamptons, Aspen, and Miami anymore

September 9, 2025
edit post
Stripe is already a payments colossus. Now it wants to make stablecoins the backbone of global commerce

Stripe is already a payments colossus. Now it wants to make stablecoins the backbone of global commerce

0
edit post
SK Hynix shares hit 25-year high, Samsung also surges as chipmakers partner with OpenAI

SK Hynix shares hit 25-year high, Samsung also surges as chipmakers partner with OpenAI

0
edit post
2026 Tax Calculator | One Big Beautiful Bill Tax Calculator

2026 Tax Calculator | One Big Beautiful Bill Tax Calculator

0
edit post
Tokenized Money Market Funds Emerge, Piloted by Industry Big Whigs

Tokenized Money Market Funds Emerge, Piloted by Industry Big Whigs

0
edit post
Ten Grocery Items You Can Get for Less than  shipped!

Ten Grocery Items You Can Get for Less than $2 shipped!

0
edit post
Dublin biotech Aerska launches with €17.8M Seed round to tackle Alzheimer’s and Parkinson’s 

Dublin biotech Aerska launches with €17.8M Seed round to tackle Alzheimer’s and Parkinson’s 

0
edit post
SK Hynix shares hit 25-year high, Samsung also surges as chipmakers partner with OpenAI

SK Hynix shares hit 25-year high, Samsung also surges as chipmakers partner with OpenAI

October 1, 2025
edit post
Investing Lessons From Video Game Economies: What Fortnite and Roblox Can Teach You About Money

Investing Lessons From Video Game Economies: What Fortnite and Roblox Can Teach You About Money

October 1, 2025
edit post
Pi Network arms its testnet with a DEX and AMM for DeFi innovation

Pi Network arms its testnet with a DEX and AMM for DeFi innovation

October 1, 2025
edit post
Investor Purchases Surge Despite Mortgage Rates—What’s Driving It?

Investor Purchases Surge Despite Mortgage Rates—What’s Driving It?

October 1, 2025
edit post
Judge nixes ex-Well Fargo broker’s tax write-off claim

Judge nixes ex-Well Fargo broker’s tax write-off claim

October 1, 2025
edit post
Why Do The Most Successful People Sleep So Much?

Why Do The Most Successful People Sleep So Much?

October 1, 2025
The Adviser Magazine

The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.

CATEGORIES

  • 401k Plans
  • Business
  • College
  • Cryptocurrency
  • Economy
  • Estate Plans
  • Financial Planning
  • Investing
  • IRS & Taxes
  • Legal
  • Market Analysis
  • Markets
  • Medicare
  • Money
  • Personal Finance
  • Social Security
  • Startups
  • Stock Market
  • Trading

LATEST UPDATES

  • SK Hynix shares hit 25-year high, Samsung also surges as chipmakers partner with OpenAI
  • Investing Lessons From Video Game Economies: What Fortnite and Roblox Can Teach You About Money
  • Pi Network arms its testnet with a DEX and AMM for DeFi innovation
  • Our Great Privacy Policy
  • Terms of Use, Legal Notices & Disclosures
  • Contact us
  • About Us

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.